Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.24.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Total revenue $ 2,627 $ 1,561
Costs of revenue 784 265
Gross profit 1,843 1,296
Operating expenses:    
Research and development 8,713 6,450
General and administrative 4,222 3,990
Sales and marketing 1,137 1,336
Grant and contract expenses 1,129 855
Total operating expenses 15,201 12,631
Loss from operations (13,358) (11,335)
Other income (expenses):    
Interest expense (2) (17)
Interest income 135 23
Gain (loss) on the disposal of assets 17 (1)
Change in fair value of derivative liabilities 5,718 (1,091)
Offering costs of derivative liabilities (786)
Other income (expense) 17 382
Total other income (expense), net 5,099 (704)
Net loss before income taxes (8,259) (12,039)
Provision for income taxes
Net loss (8,259) (12,039)
Deemed dividend related to beneficial conversion feature on convertible preferred stock (26) (4,450)
Net loss attributable to common stockholders $ (8,285) $ (16,489)
Net loss per share – basic and diluted    
Basic – net loss $ (2.21) $ (39.92)
Basic – deemed dividend and accretion of a discount on conversion of preferred stock (0.01) (14.75)
Basic – attributable to common stockholders (2.22) (54.67)
Diluted – net loss (3.12) (46.79)
Diluted - deemed dividend and accretion of a discount on conversion of preferred stock (0.01) (14.02)
Diluted – attributable to common stockholders $ (3.13) $ (60.81)
Weighted average common shares outstanding:    
Basic 3,736,412 301,610
Diluted 4,357,242 317,323
Product [Member]    
Total revenue $ 1,226 $ 601
Grant and Contract [Member]    
Total revenue $ 1,401 $ 960